Device Plays Integral Role in Delivering Stem Cells for its Proprietary Bulging/Herniated Disc Therapy
Jupiter, FL – May 20, 2013 – BioRestorative Therapies, Inc. (“BRT” or the “Company”) (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting agreement with Dexterity, Inc. (“Dexterity”). Dexterity is a product design and bioengineering firm that will provide services to further the development and production of BRT’s proprietary therapeutic delivery device for its intervertebral disc stem cell therapy program, “brtxDISC™,” (Disc Implanted Stem Cells).
Dexterity’s work is intended to advance the design and production of the disc therapeutic delivery device, towards a final version, to be eventually used in a clinical trial as a stem cell delivery system for the treatment of bulging and herniated discs. BRT expects to have a pre-IND/IDE meeting with the FDA to discuss the clinical trial by fourth quarter of this year.
The Company’s brtxDISC™ program is being developed as an alternative to surgical intervention for patients suffering from bulging or herniated discs and could bridge the gap between non-invasive and invasive surgical back procedures. The therapy is a regeneration repair process using a patient’s own stem cells that are implanted using BRT’s proprietary therapeutic delivery device. The Company has data on treated humans in the U.S. and is compiling results in preparation for clinical trials in the U.S.
"We are very excited to be working with BioRestorative Therapies on the development of its novel, proprietary brtxDISC™ intervertebral disc stem cell therapy,” commented Eric Simon, President of Dexterity. “Our experience with laparascopic and catheter-based devices, cell culture systems, and drug-delivery devices will assist in advancing the development and production of BRTX’s disc stem cell delivery device as the company moves through its next phase of clinical trials."
“We are fortunate to be working with Dexterity,” commented Mark Weinreb, Chief Executive Officer of BioRestorative Therapies. “With their depth of experience in 3D-CAD, biomaterials, and advanced prototyping and manufacturing, they are the perfect partner to work on the design and final engineering of our medical disc delivery device. We are confident our device will have the performance and quality to operate as intended and will be commercial-ready when we are able to launch our brtxDISC™” program.”
About Dexterity, Inc.
Dexterity, Inc. is a full-service product design and development resource. The company has extensive experience in the design of tangible goods in the medical/biotechnical, consumer, and industrial markets. Dexterity specializes in 3D-Solids CAD modeling and analysis, employing rapid prototyping and tooling technologies to accelerate products to market. Dexterity's broad manufacturing experience assists its clients in designing toward the appropriate production technology for its clients and consumers needs. The company has designed and implemented a diverse range of medical and biotechnical products including in-vitro diagnostic systems, laparoscopic instrumentation, high-performance cell culture ware, drug-delivery devices, and various implantable products.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (“BRT”), http://www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
• brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
• ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
• brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.